Corrections staff cite diversion of medication for opioid use disorder (MOUD) (e.g., buprenorphine) as a reason for not offering treatment with these medications in jails and prisons. In a 2023 study, researchers from the University of Massachusetts outline key steps MOUD program staff can implement to prevent diversion. The study also provides guidance to corrections and lawmakers as they consider establishing and expanding MOUD treatment in correctional settings.
